Randomized Evaluation of Beta Blocker and ACEI/ARB Treatment in MINOCA Patients - MINOCA-BAT

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 198 participants.

Also called NCT03686696

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 198 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03686696
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, New Zealand, Norway, Spain, Sweden (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03686696. Randomized; no masking; primary purpose treatment. Start 2018-12-16 (actual); primary completion 2023-05-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Evaluation of Beta Blocker and ACEI/ARB Treatment in MINOCA Patients - MINOCA-BAT
Acronym
MINOCA-BAT
Condition
Myocardial Infarction With Non-obstructive Coronary Arteries
Intervention (Drug)
Beta blocker
Intervention (Drug)
ACEI
Intervention (Drug)
ARB
Lead sponsor
Uppsala University (class: other)
Collaborator
Karolinska Institutet (class: other)
Collaborator
Göteborg University (class: other)
Collaborator
University of Leeds (class: other)
Collaborator
University of Adelaide (class: other)
Collaborator
Oslo University Hospital (class: other)
Collaborator
New York University (class: other)

Record details

Record id
cardio:ct-nct03686696
Content hash
fd3740e693c6b34448a80be687ddef999e402e4876fdcf0d98c8214a89a91fe1